Study of JNJ-74856665 in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

2024-513918-35-00 Protocol 74856665AML1001 Human pharmacology (Phase I) - First administration to humans Ended

Start 22 Dec 2020 · End 25 Aug 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 74856665AML1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 1
Countries 1
Sites 1

Acute myeloid leukemia or Myelodysplastic syndrome

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
22 Dec 2020 → 25 Aug 2025
Decision date (initial)
2024-07-26
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-513918-35-00
EudraCT number
2020-002375-35

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Acute myeloid leukemia or Myelodysplastic syndrome

VersionLevelCodeTermSystem organ class
21.0 LLT 10000886 Acute myeloid leukemia 10029104
27.0 PT 10028533 Myelodysplastic syndrome 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 1 1
Rest of world 0

Investigational sites

Spain

1 site · Ended
Clinica Universidad De Navarra
Hematology department, Pio XII Etorbidea 36, 31008, Pamplona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2020-12-22 2025-08-25 2021-01-27 2022-05-24

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-22 Spain Acceptable with conditions
2024-07-26
2024-07-26